Literature DB >> 27192549

Conformational States of HIV-1 Reverse Transcriptase for Nucleotide Incorporation vs Pyrophosphorolysis-Binding of Foscarnet.

Kalyan Das1, Jan Balzarini2, Matthew T Miller1, Anita R Maguire3, Jeffrey J DeStefano4, Eddy Arnold1.   

Abstract

HIV-1 reverse transcriptase (RT) catalytically incorporates individual nucleotides into a viral DNA strand complementing an RNA or DNA template strand; the polymerase active site of RT adopts multiple conformational and structural states while performing this task. The states associated are dNTP binding at the N site, catalytic incorporation of a nucleotide, release of a pyrophosphate, and translocation of the primer 3'-end to the P site. Structural characterization of each of these states may help in understanding the molecular mechanisms of drug activity and resistance and in developing new RT inhibitors. Using a 38-mer DNA template-primer aptamer as the substrate mimic, we crystallized an RT/dsDNA complex that is catalytically active, yet translocation-incompetent in crystals. The ability of RT to perform dNTP binding and incorporation in crystals permitted obtaining a series of structures: (I) RT/DNA (P-site), (II) RT/DNA/AZTTP ternary, (III) RT/AZT-terminated DNA (N-site), and (IV) RT/AZT-terminated DNA (N-site)/foscarnet complexes. The stable N-site complex permitted the binding of foscarnet as a pyrophosphate mimic. The Mg(2+) ions dissociated after catalytic addition of AZTMP in the pretranslocated structure III, whereas ions A and B had re-entered the active site to bind foscarnet in structure IV. The binding of foscarnet involves chelation with the Mg(2+) (B) ion and interactions with K65 and R72. The analysis of interactions of foscarnet and the recently discovered nucleotide-competing RT inhibitor (NcRTI) α-T-CNP in two different conformational states of the enzyme provides insights for developing new classes of polymerase active site RT inhibitors.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27192549      PMCID: PMC4992415          DOI: 10.1021/acschembio.6b00187

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  52 in total

1.  PPi analogs as inhibitors of human T-lymphotropic virus type III reverse transcriptase.

Authors:  L Vrang; B Oberg
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

2.  Phosphonoformic acid inhibits viral replication by trapping the closed form of the DNA polymerase.

Authors:  Karl E Zahn; Egor P Tchesnokov; Matthias Götte; Sylvie Doublié
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

3.  Inhibition of HIV-1 reverse transcriptase-catalyzed DNA strand transfer reactions by 4-chlorophenylhydrazone of mesoxalic acid.

Authors:  W R Davis; J Tomsho; S Nikam; E M Cook; D Somand; J A Peliska
Journal:  Biochemistry       Date:  2000-11-21       Impact factor: 3.162

4.  Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates.

Authors:  J W Mellors; H Z Bazmi; R F Schinazi; B M Roy; Y Hsiou; E Arnold; J Weir; D L Mayers
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

5.  HIV-1 reverse transcriptase can simultaneously engage its DNA/RNA substrate at both DNA polymerase and RNase H active sites: implications for RNase H inhibition.

Authors:  Greg L Beilhartz; Michaela Wendeler; Noel Baichoo; Jason Rausch; Stuart Le Grice; Matthias Götte
Journal:  J Mol Biol       Date:  2009-03-13       Impact factor: 5.469

6.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.

Authors:  H Huang; R Chopra; G L Verdine; S C Harrison
Journal:  Science       Date:  1998-11-27       Impact factor: 47.728

7.  Trapping HIV-1 reverse transcriptase before and after translocation on DNA.

Authors:  Stefan G Sarafianos; Arthur D Clark; Steve Tuske; Christopher J Squire; Kalyan Das; Dequan Sheng; Palanichamy Ilankumaran; Andagar R Ramesha; Heiko Kroth; Jane M Sayer; Donald M Jerina; Paul L Boyer; Stephen H Hughes; Eddy Arnold
Journal:  J Biol Chem       Date:  2003-01-28       Impact factor: 5.157

8.  Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.

Authors:  G Tachedjian; J Mellors; H Bazmi; C Birch; J Mills
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

9.  Exploring the role of the α-carboxyphosphonate moiety in the HIV-RT activity of α-carboxy nucleoside phosphonates.

Authors:  Nicholas D Mullins; Nuala M Maguire; Alan Ford; Kalyan Das; Eddy Arnold; Jan Balzarini; Anita R Maguire
Journal:  Org Biomol Chem       Date:  2016-02-28       Impact factor: 3.876

10.  Selection of primer-template sequences that bind human immunodeficiency virus reverse transcriptase with high affinity.

Authors:  Jeffrey J DeStefano; Jason V Cristofaro
Journal:  Nucleic Acids Res       Date:  2006-01-05       Impact factor: 16.971

View more
  21 in total

1.  A new general method for simultaneous fitting of temperature and concentration dependence of reaction rates yields kinetic and thermodynamic parameters for HIV reverse transcriptase specificity.

Authors:  An Li; Jessica L Ziehr; Kenneth A Johnson
Journal:  J Biol Chem       Date:  2017-03-02       Impact factor: 5.157

2.  Through-bond effects in the ternary complexes of thrombin sandwiched by two DNA aptamers.

Authors:  Andrea Pica; Irene Russo Krauss; Valeria Parente; Hisae Tateishi-Karimata; Satoru Nagatoishi; Kouhei Tsumoto; Naoki Sugimoto; Filomena Sica
Journal:  Nucleic Acids Res       Date:  2016-11-28       Impact factor: 16.971

Review 3.  Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance.

Authors:  Francesc Xavier Ruiz; Eddy Arnold
Journal:  Curr Opin Struct Biol       Date:  2020-01-11       Impact factor: 6.809

4.  Structural Basis of HIV-1 Inhibition by Nucleotide-Competing Reverse Transcriptase Inhibitor INDOPY-1.

Authors:  F Xavier Ruiz; Anthony Hoang; Kalyan Das; Eddy Arnold
Journal:  J Med Chem       Date:  2019-10-25       Impact factor: 7.446

5.  Structure of HIV-1 reverse transcriptase/d4TTP complex: Novel DNA cross-linking site and pH-dependent conformational changes.

Authors:  Sergio E Martinez; Joseph D Bauman; Kalyan Das; Eddy Arnold
Journal:  Protein Sci       Date:  2018-12-22       Impact factor: 6.725

6.  Rate-limiting Pyrophosphate Release by HIV Reverse Transcriptase Improves Fidelity.

Authors:  An Li; Shanzhong Gong; Kenneth A Johnson
Journal:  J Biol Chem       Date:  2016-10-24       Impact factor: 5.157

7.  Structural Insights into HIV Reverse Transcriptase Mutations Q151M and Q151M Complex That Confer Multinucleoside Drug Resistance.

Authors:  Kalyan Das; Sergio E Martinez; Eddy Arnold
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

8.  Guanine α-carboxy nucleoside phosphonate (G-α-CNP) shows a different inhibitory kinetic profile against the DNA polymerases of human immunodeficiency virus (HIV) and herpes viruses.

Authors:  Jan Balzarini; Michael Menni; Kalyan Das; Lizette van Berckelaer; Alan Ford; Nuala M Maguire; Sandra Liekens; Paul E Boehmer; Eddy Arnold; Matthias Götte; Anita R Maguire
Journal:  Biochem Pharmacol       Date:  2017-04-06       Impact factor: 5.858

Review 9.  Alpha-carboxynucleoside phosphonates: direct-acting inhibitors of viral DNA polymerases.

Authors:  Jan Balzarini; Alan Ford; Nuala M Maguire; Jubi John; Kalyan Das; Eddy Arnold; Wim Dehaen; Anita Maguire
Journal:  Future Med Chem       Date:  2019-01-16       Impact factor: 3.808

10.  Loss of DNA methylation in zebrafish embryos activates retrotransposons to trigger antiviral signaling.

Authors:  Yelena Chernyavskaya; Raksha Mudbhary; Chi Zhang; Debra Tokarz; Vinitha Jacob; Smita Gopinath; Xiaochen Sun; Shuang Wang; Elena Magnani; Bhavani P Madakashira; Jeffrey A Yoder; Yujin Hoshida; Kirsten C Sadler
Journal:  Development       Date:  2017-07-11       Impact factor: 6.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.